About: Challenges in early phase clinical trials for childhood cancer during the COVID-19 pandemic: a report from the new agents group of the Spanish Society of Paediatric Haematology and Oncology (SEHOP)

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Challenges in early phase clinical trials for childhood cancer during the COVID-19 pandemic: a report from the new agents group of the Spanish Society of Paediatric Haematology and Oncology (SEHOP) Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
title	Challenges in early phase clinical trials for childhood cancer during the COVID-19 pandemic: a report from the new agents group of the Spanish Society of Paediatric Haematology and Oncology (SEHOP)
Creator	Bautista, · Castañeda, · Cañete, · De Rojas, · Guerra-García, · Hladun, · Juan-Ribelles, · Molero, · Moreno, · Pérez-Martínez, · Rubio-San-Simón, A Verdú-Amorós, ·
source	Medline; PMC
abstract	PURPOSE: The COVID-19 pandemic has forced healthcare stakeholders towards challenging decisions. We analyse the impact of the pandemic on the conduct of phase I–II trials for paediatric cancer during the first month of state of alarm in Spain. METHODS: A questionnaire was sent to all five ITCC-accredited Spanish Paediatric Oncology Early Phase Clinical Trial Units, including questions about impact on staff activities, recruitment, patient care, supply of investigational products, and legal aspects. RESULTS: All units suffered personnel shortages and difficulties in enrolling patients, treatment continuity, or performing trial assessments. Monitoring activity was frequently postponed (73%), and 49% of on-going trials interrupted recruitment. Only two patients could be recruited during this period (75% reduction in the expected rate). CONCLUSIONS: The COVID-19 crisis has significantly impacted clinical research practice and access to innovation for children with cancer. Structural and functional changes are under way to better cope with the expected future restrictions.
has issue date	2020-05-29(xsd:dateTime)
bibo:doi	10.1007/s12094-020-02399-3
bibo:pmid	32472454
has license	no-cc
sha1sum (hex)	21aae7243eb91934f0463d4f89c27c2d2bfa096e
schema:url	https://doi.org/10.1007/s12094-020-02399-3
resource representing a document's title	Challenges in early phase clinical trials for childhood cancer during the COVID-19 pandemic: a report from the new agents group of the Spanish Society of Paediatric Haematology and Oncology (SEHOP)
has PubMed Central identifier	PMC7258607
has PubMed identifier	32472454
schema:publication	Clin Transl Oncol
resource representing a document's body	covid:21aae7243eb91934f0463d4f89c27c2d2bfa096e#body_text
is schema:about of	named entity 'Oncology' named entity 'cancer' named entity 'INVESTIGATIONAL' named entity 'FUNCTIONAL' named entity 'PHASE' named entity 'INNOVATION' named entity 'PERFORMING' named entity 'CHANGES' named entity 'COVID-19' named entity 'questionnaire' named entity 'cancer' named entity 'activities' named entity 'aspects' named entity 'activity' named entity 'Results' named entity 'Units' named entity 'interrupted' named entity 'questionnaire' named entity 'patient care' named entity 'Paediatric Oncology' named entity 'COVID-19 pandemic' named entity 'Paediatric' named entity 'Oncology' named entity 'haematological' named entity 'SIV' named entity 'Amgen' named entity 'Spain' named entity 'MVs' named entity 'clinical trial' named entity 'COVID-19 pandemic' named entity 'Novartis' named entity 'COVID-19 pandemic' named entity 'state of alarm' named entity 'patient care' named entity 'SARS-CoV-2' named entity 'Spain' named entity 'patient safety' named entity 'Children with Cancer' named entity 'COVID-19 disease' named entity 'long-term' named entity 'ethical standards' named entity 'COVID' named entity 'public health' named entity 'healthcare facilities' named entity 'drug development' named entity 'Celgene' named entity 'Descriptive statistics' named entity 'paediatric oncology' named entity 'Amgen' named entity 'ethics' named entity 'elective procedures' named entity 'Amgen' named entity 'Jazz Pharmaceuticals' named entity 'clinical trial' named entity 'clinical trials' named entity 'homeworking' named entity 'multidisciplinary' named entity 'Informed consent' named entity 'COVID' named entity 'pharmaceutical companies' named entity 'homeworking' named entity 'Clinical trials' named entity 'refractory' named entity 'COVID' named entity 'European Medicines Agency' named entity 'COVID-19' named entity 'clinical practice' named entity 'paediatric cancer' named entity 'dinutuximab' named entity 'Medical Devices'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software